Abstract Details

Title Improved Walking Speed in Prolonged-Release Fampridine Timed Walk Responders May Translate to Improvements in Functional Walking Ability

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 099

Objective

Background BACKGROUND: Functional walking scales have been used to generalize impairments in walking to limitations in activities of daily living. Recently, walking speeds (WS) were classified into Modified Functional Walking Categories (FWCs) in MS.

Design/Methods DESIGN/METHODS: Patients with MS who could complete the Timed 25-foot Walk (T25FW) in 8-45s were randomised to placebo (n=190) or PR-fampridine 10 mg (n=343) twice daily. A Timed-walk Responder (TWR) walked faster on the T25FW on- versus off-treatment. Mean baseline (BL) and on-treatment WS were used to group placebo patients, PR-fampridine Timed-walk non-responders (TWnR), and PR-fampridine TWRs into 5 FWCs: limited household walker (LHW: <0.48 m/s), unlimited household walker (UHW: ?0.48 to <1.04 m/s), most-limited community walker (MLCW: ?1.04 to <1.35 m/s), least-limited community walker (LLCW: ?1.35 to <1.63 m/s), and unlimited community walker (UCW: ?1.63 m/s).

Results RESULTS: The median EDSS was 6.0. Among patients in the placebo (n=190), TWnR (n=214), and TWR (n=129) groups, 24.2%, 29.0%, 27.1% patients were LHW at BL; 75.8%, 69.2%, 72.9% patients were UHW; and 0%, 1.9%, and 0% patients were MLCW. More TWRs (34.8%) improved by ?1 FWC than TWnRs (10.3%) or placebo (10.5%) patients. Among LHW at BL, more TWRs (51.4%) than TWnR (16.1%) or placebo (19.6%) patients improved to UHW. Among UHW at BL, more TWRs (27.7%) than TWnRs (7.4%) or placebo (7.6%) patients improved to MLCW. Among UHW at BL, 2.1%, 4.1%, and 0% of placebo, TWnRs, and TWRs worsened. One TWR improved from UHW to UCW during treatment.

Conclusions CONCLUSIONS: More PR-fampridine TWRs had improvement in FWC status, including transition to community walker status, than PR-fampridine TWnRs or placebo patients.

Authors/Disclosures
PRESENTER	No disclosure on file
Sakhina Begum-Haque, PhD (Dartmouth Med School)	No disclosure on file
Andrew D. Goodman, MD, FAAN (University of Rochester Dept. Neurology)	Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Swan Bio. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IMCYSE. Dr. Goodman has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Goodman has received research support from Atara. The institution of Dr. Goodman has received research support from Genzyme. The institution of Dr. Goodman has received research support from EMD-Serono.
Marco Capobianco, MD	No disclosure on file

��ɫ��

��ɫ��